Luminaries in Structural Heart.

About Luminaries in Structural Heart.

The Luminaries in Structural Heart podcast offers an inside look at the people shaping the future of cardiology. Through engaging and thoughtful conversations, the series explores each guest’s personal journey, academic milestones, and perspectives on the most relevant and timely topics in contemporary invasive cardiology. Hosted by distinguished cardiac surgeons and interventional cardiologists with deep expertise in structural heart interventions, the podcast delivers meaningful dialogue, global insights, and expert commentary from some of the field’s most influential voices.

Publisher

SH

Category

health & fitness

Language

en

Explicit

No

First episode

11 Apr 2024

Latest episode

22 Oct 2026

Latest episodes

19 episodes in the feed.

1. 

   22 Oct 2026

   HALT and Thrombosis After TAVR: What Is Really Happening?

   In this episode, Dr. Ashwin Murthy and Dr. Nima Aghili explore HALT after TAVR, including its imaging characteristics, contributing factors, clinical significance, and natural progression. They discuss when to monitor versus treat HALT, anticoagulation strategies, and key insights from the GALILEO trial.

2. 

   28 Sept 2026

   Early Career Growth & Leadership

   Join host Andrea Scotti and guest Puja Parikh as they discuss career growth in cardiology—covering mentorship, research, publishing, and leadership strategies to help early career physicians build impactful, successful paths in structural heart. #StructuralHeart, #InterventionalCardiology, #LuminariesInStructuralHeart, #MedEd, #CardiologyCommunity

3. 

   21 Sept 2026

   Coronary Cannulation and Access Strategies After TAVR

   Join Dr. Guilherme Attizzani and Dr. Jai Parekh for an expert discussion on coronary cannulation and access strategies after TAVR, highlighting commissural alignment, device evolution, procedural techniques, and evidence demonstrating reliable coronary access and improved outcomes with contemporary Evolut platforms.

4. 

   13 Aug 2026

   Does SMART Translate? A Real-World Look at Small-Annulus TAVR

   In this new episode, Marcus R. Burns, DNP, RCIS, AACC, Structural Interventional Cardiology at Minneapolis Heart Institute (MHI)/Abbott Northwestern, shares how his team evaluated their own small-annulus TAVR outcomes and compared their real-world experience with findings from the SMART trial. Marcus discusses what prompted the analysis, how his team collected and followed their institutional data through three years, and how their findings compared with trends observed in SMART. He also shares how these insights have influenced their approach to valve selection, hemodynamics, longitudinal follow-up, and heart-team decision-making for patients with small annuli.

5. 

   22 Jun 2026

   TAV-in-SAV: Techniques, Sizing, and Outcomes

   Angel Caldera, MD, interviews Paul Mahoney, MD, on TAV-in-SAV for failed bioprosthetic valves. They review patient selection, valve sizing, and coronary obstruction risk using CT planning. The discussion highlights leaflet modification, stroke considerations, anticoagulation strategies, and the ever-evolving balance between redo surgery and transcatheter approaches.

6. 

   9 Mar 2026

   Post-TAVR Optimization ft. Sarah Kennedy, NP and Jessica Kiska, NP

   Join Sarah Kennedy and Jessica Kiszka as they explore best practices for optimizing post-TAVR care. From discharge planning to long-term follow-up, this episode highlights practical strategies to improve patient outcomes, streamline workflows, and support lifetime management in today’s evolving structural heart landscape.

7. 

   9 Mar 2026

   Why is bicuspid still a challenge? ft. Lucas Seibolt, MD and Rony Lahoud, MD

   Dr. Lucas Seibolt and Dr. Rony Lahoud examine the complexities of treating bicuspid aortic valve disease in the TAVR era. This episode dives into anatomical considerations, procedural nuances, and emerging data—offering insights to help clinicians navigate one of the field’s most persistent challenges.

8. 

   7 Nov 2025

   Breaking Barriers: Women with AS – A Conversation with Dr. Kendra Grubb and Dr. Janine Eckstein

   In this episode, Dr. Kendra Grubb and Dr. Janine Eckstein take a closer look at the unique challenges faced by women with aortic stenosis (AS) and explore how transcatheter aortic valve replacement (TAVR) is transforming outcomes for female patients. They dive into the disparities in clinical outcomes between women undergoing surgical aortic valve replacement (SAVR) versus TAVR, and share their insights on how tailored approaches to care can help improve patient outcomes. For additional context, check out this meta-analysis by Panoulas VF et al., which highlights how women have historically shown worse clinical outcomes with surgery compared to TAVR. Tune in to hear Dr. Grubb and Dr. Eckstein’s perspectives on this important topic and learn how advancements in structural heart therapies are helping to address gender-specific challenges in treating AS.

9. 

   19 May 2025

   Mindset Matters: Stress on Cardiovascular Interventions

   In this episode of the Structural Heart Podcast: Luminaries Series, host Dr. Daniel O’Hair welcomes Dr. Daniel Spoon, a unique voice in the field of interventional cardiology, to discuss the often-overlooked mental stress faced by interventional cardiologists. The conversation delves into the high-pressure nature of cardiovascular interventions, where physicians must navigate unpredictable emergencies, long hours, and life-and-death situations—all while maintaining composure and precision. Dr. Spoon shares his unique journey from orthopedic surgery to interventional cardiology, highlighting the emotional and psychological demands of the profession and the strategies he has developed to manage them. The discussion explores burnout, work-life balance, and the importance of mental resilience in sustaining a long and fulfilling career. Dr. Spoon draws from sports psychology principles to explain how managing stress, maintaining self-awareness, and fostering team cohesion can enhance performance and well-being. The episode also emphasizes the need for better mental health training in medical education, equipping future physicians with the tools to handle stress effectively. Ultimately, this episode serves as a candid and insightful reflection on the challenges of modern cardiology and the mindset required to thrive in this demanding field. UC202506521 EN.

10. 

    18 Apr 2025

    Clinical Insights from the SMART 2y and Low Risk 5y TAVR Trials

    Join hosts Dr. Dan O'Hair and Dr. Suzanne Baron in this compelling episode as they engage with esteemed guests Dr. Howard Herrmann and Dr. Michael Reardon, principal investigators of the SMART and Evolut Low Risk trials, respectively. Together, they explore the evolving landscape of structural heart interventions, analyzing groundbreaking data, clinical implications, and the future of patient care. From trial design to real-world applications, Dr. Herrmann and Dr. Reardon share firsthand insights into the science shaping tomorrow’s standards in cardiology. Whether you're a clinician, researcher, or simply passionate about cardiovascular innovation, this episode delivers invaluable perspectives straight from the frontlines of clinical discovery.

11. 

    11 Feb 2025

    Pioneering Structural Heart Interventions, the journey of Dr. Ashok Seth on TAVR, Innovation & the Future of Cardiology

    This podcast episode features our host, Dr. Kendra Grub, conversing with our guest, Dr. Ashok Seth, a renowned interventional cardiologist. Dr. Seth discusses his pioneering work introducing TAVR and other interventional technology to India and Asia over the past 30 years.Dr. Seth performed the first TAVR CoreValve self-expandable in India in 2004, marking a significant milestone in interventional cardiology. Social attitudes and a lack of reimbursement are additional barriers to TAVI adoption among the elderly in India; India has a unique patient population with more bicuspid cases and smaller annuli, which influences valve choice during procedures. Dr. Seth emphasizes tailoring valve selection to patient anatomy and lifetime management needs.The podcast also touches on the future of structural heart interventions, with Dr. Seth expressing excitement about advancements in mitral and tricuspid valve technologies.Dr. Seth advises emerging TAVI programs to focus on robust systems, standardized protocols, and a hub-and-spoke model for safe and effective outcomes.

12. 

    29 Jan 2025

    Women and aortic stenosis, evidence practice review of the SMART trial results.

    In this episode, Dr. Roxana Mehran and Dr. Martha Gulati engage in a captivating discussion about how the SMART Trial is making a difference for women with aortic stenosis.[†,1] The SMART Trial is the largest, most rigorous clinical trial to date to randomize patients to the two most widely used TAVR devices, and to enroll predominantly women.[1] Featured faculty:Martha Gulati, MD MS FACC FAHA FASPC FESCDirector of Preventive Cardiology and Professor of Cardiology, Cedars Sinai Smidt Heart InstituteAssociate Director, Barbra Streisand Women’s Heart CenterAssociate Director, Preventive and Cardiac Rehabilitation CenterAnita Dann Friedman Endowed Chair in Women’s Cardiovascular Medicine & ResearchRoxana Mehran, MD, FACC, FESC, FAHA, MSCAIDirector, Women's Heart and Vascular Center at Mount Sinai Fuster Heart HospitalDirector, The Center for Interventional Cardiovascular Research and Clinical TrialsProfessor of Medicine (Cardiology) and Population Health Science and Policy, Icahn School of Medicine at Mount Sinai Disclosures: Faculty for this event are consultants for Medtronic and compensated for this event. Dr. Gulati: I serve on advisory boards for Novartis, Esperion, New Amsterdam and Medtronic. I serve on a DSMB for Merck. All except Medtronic unrelated to our discussion Dr. Mehran reports institutional research payments from: Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; Personal fees from: Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk ; Equity <1% in: Elixir Medical, Stel, ControlRad (spouse) ; No Fees from: SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director) ; Honorarium: AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program) TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. †Evolut™ TAVR is indicated to treat patients who have been diagnosed with symptomatic severe aortic stenosis.1. Tchétché D, Mehran R, Blackman DJ, et al. Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial. JAMA Cardiol. Published online October 9, 2024. The Medtronic CoreValve™ Evolut™ R, Evolut™ PRO+, and Evolut™ FX Systems are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy. The Medtronic CoreValve Evolut R, Evolut PRO+, and Evolut FX Systems are indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (e.g., STS predicted risk of operative mortality score ≥ 8% or at a ≥ 15% risk of mortality at 30 days).

13. 

    17 Dec 2024

    Evolution of TAVR valve design and the implications for valve durability and lifetime management.

    Cardiovascular experts Dr. Srinivas Iyengar and Dr. Kasi Ramanathan discuss the evolution of TAVR valve design, revealing how nuanced valve durability and patient selection drive long-term success and freedom from reintervention.

14. 

    21 Nov 2024

    Coronary Access Post-TAVR and Other Hot Topics with Dr. Attizzani

    Dr. Guilherme Attizzani shares his expert insights on building a successful structural heart program, optimizing coronary access, and delivering exceptional care through innovative strategies and groundbreaking research.

15. 

    4 Nov 2024

    Navigating Lifetime Management of TAVR with Dr. Michael Reardon

    Join Dr. Puja Parikh,  Director of the TAVR program at Stony Brook University Hospital, as she hosts a captivating conversation with the renowned cardiac surgeon Dr. Michael Reardon. Dr. Reardon, a leader in cardiac surgery and structural heart innovation, shares his remarkable journey into the field, from an unexpected childhood incident to becoming a pivotal figure in the transcatheter aortic valve replacement (TAVR) revolution. In this insightful episode, Dr. Reardon reflects on the evolution of cardiac surgery training and the transformative impact of TAVR. He discusses the importance of adapting to new technologies, the future of cardiac surgery education, and the potential challenges and opportunities facing young surgeons today. The conversation also delves into the role of AI in patient care and the ongoing advancements in valve technologies. Dr. Reardon offers invaluable advice to early-career colleagues and trainees, emphasizing the importance of open-mindedness, hands-on experience, and collaboration between cardiologists and surgeons. This episode is a must-listen for anyone interested in the future of cardiac care and the dynamic world of structural heart interventions.

16. 

    18 Sept 2024

    Modern Perspectives on Cardiothoracic and Structural Heart Innovation

    In this episode of the Structural Heart podcast, world-renowned cardiothoracic surgeons Dr. Patrick McCarthy and Dr. Dan O'Hair discuss a wide range of topics centered around advancing technology within the surgical and structural heart landscape. The episode starts with Dr. McCarthy and Dr. O'Hair discussing emerging surgical mitral technology alongside how lulls in procedures associated with the COVID-19 pandemic afforded them the extra time to analyze their own program data and better understand which patients benefited most from various cardiac therapies. Next, the conversation shifts from mitral to aortic as they discuss consistent themes and fundamentals that are shared between open-heart aortic valve replacements and transcatheter aortic valve replacements. Both physicians speak to the importance of practicing evidence-based medicine within the cardiovascular space and making decisions rooted in data regarding critical procedures like valve replacements. The episode concludes with light-hearted conversation lessons they wish they had learned earlier in their careers and want to pass along to an emerging generation of cardiovascular physicians.

17. 

    1 Aug 2024

    Lifetime Management : TAVR considerations for Future Interventions

    Join us for an exciting discussion led by Dr Hemal Gada, an Interventional Cardiologist from UPMC,Pennsylvania, and Dr. Gilbert Tang, a Cardiac Surgeon from Mount Sinai in NY. The conversation will explore how the evolving TAVR landscape shapes  Aortic Stenosis interventions. From the early days to the present, a significant number of patients have been treated, generating a wealth of data on efficiencies, PVL, Hemodynamic impact, and clinical results. What will the data reveal? Will we see a 'TAVR Tsunami'  of patients or a more gradual increase in returning patients? Are there any predictors that can help us identify the right patient? What role does Neosinus flow and thrombosis play in this context?Does valve selection influence future events? How do new generations of self-expanding valves influence clinical results? This is an opportunity to analyze mid-long-term data and explore these crucial topics. What do we know about explant TAVR? These are just a few crucial topics explored in this upcoming edition of the Structural Heart Podcast. We invite you to join us for a deep dive into these issues in TAVR and Aortic Stenosis interventions.

18. 

    6 May 2024

    SMART trial: Contemporary Critique of Trial Design & Findings

    Don't miss this crucial episode of the Structural Heart Podcast, where we dive into the SMART trial data and evaluate it from two perspectives. We're honored to be joined by cardiothoracic surgeon Dr. Dan O'Hair and one of the SMART trial's PIs, Dr. Hemal Gada. This discussion is not just about the Evolut and Sapien valve platforms but also about what this data means for patients. Stay tuned as they share their critical interpretations of the SMART Trial.

19. 

    11 Apr 2024

    CV Review Low Risk trials - TAVR analysis. Host:Dan O'Hair, MD, featured guest: Hemal Gada, MD

    In this episode, we're going to do a deep dive into the Low-Risk TAVR trials for intra-annular Ballon Expandable and Self Expandable supra-annular, and I'm going to be joined by our special guest, Dr. Hemal Gada, renowned interventional cardiologist, and structuralist and president of the Heart and Vascular Institute atIP{MC in Harrisburg, Pennsylvania. We're gonna cover all kinds of topics like death and stroke thrombosis whose valves are failing, and why.

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

4 ratings

Spotify

4.8 / 5

4 ratings

Podcast Authority Score: 9 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

6

Social presence

0

YouTube

0

Engagement

32